DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $167,799,244 | +3.6% | 676,336 | +0.3% | 2.77% | +8.6% |
| Q2 2023 | $161,896,320 | -4.6% | 674,568 | +0.2% | 2.55% | -11.1% |
| Q1 2023 | $169,716,405 | -5.3% | 673,371 | -0.3% | 2.87% | -10.6% |
| Q4 2022 | $179,239,321 | +1.8% | 675,304 | -1.0% | 3.21% | -6.6% |
| Q3 2022 | $176,146,000 | +1.0% | 681,971 | -0.9% | 3.44% | +7.8% |
| Q2 2022 | $174,437,000 | -14.3% | 688,060 | -0.8% | 3.19% | -0.4% |
| Q1 2022 | $203,485,000 | -10.4% | 693,705 | +0.5% | 3.21% | -5.7% |
| Q4 2021 | $227,054,000 | +7.2% | 690,113 | -0.8% | 3.40% | -3.4% |
| Q3 2021 | $211,801,000 | +12.1% | 695,705 | -1.2% | 3.52% | +10.3% |
| Q2 2021 | $188,948,000 | +19.3% | 704,081 | +0.1% | 3.19% | +9.2% |
| Q1 2021 | $158,337,000 | +1.1% | 703,469 | -0.2% | 2.92% | -4.5% |
| Q4 2020 | $156,548,000 | +2.9% | 704,727 | -0.3% | 3.06% | -6.8% |
| Q3 2020 | $152,168,000 | +21.3% | 706,672 | -0.4% | 3.28% | +11.7% |
| Q2 2020 | $125,474,000 | +27.0% | 709,574 | -0.6% | 2.94% | +6.5% |
| Q1 2020 | $98,814,000 | -10.1% | 713,923 | -0.3% | 2.76% | +12.8% |
| Q4 2019 | $109,936,000 | +6.3% | 716,293 | +0.0% | 2.45% | -0.9% |
| Q3 2019 | $103,448,000 | +0.8% | 716,246 | -0.2% | 2.47% | -1.2% |
| Q2 2019 | $102,619,000 | +6.7% | 718,014 | -1.4% | 2.50% | +3.6% |
| Q1 2019 | $96,147,000 | +25.8% | 728,274 | -1.7% | 2.41% | +12.0% |
| Q4 2018 | $76,399,000 | -5.3% | 740,873 | -0.2% | 2.15% | +12.1% |
| Q3 2018 | $80,650,000 | +9.7% | 742,226 | -0.4% | 1.92% | +1.1% |
| Q2 2018 | $73,516,000 | +0.0% | 744,999 | -0.8% | 1.90% | +0.4% |
| Q1 2018 | $73,513,000 | +6.2% | 750,816 | +0.7% | 1.89% | +2.5% |
| Q4 2017 | $69,210,000 | +7.1% | 745,635 | -1.0% | 1.85% | +8.6% |
| Q3 2017 | $64,639,000 | +4.1% | 753,542 | +2.5% | 1.70% | -2.0% |
| Q2 2017 | $62,069,000 | -0.5% | 735,504 | +0.8% | 1.74% | -2.9% |
| Q1 2017 | $62,395,000 | +10.7% | 729,515 | +0.7% | 1.79% | +5.9% |
| Q4 2016 | $56,386,000 | +0.2% | 724,389 | +0.9% | 1.69% | -13.4% |
| Q3 2016 | $56,294,000 | -23.2% | 718,112 | -1.1% | 1.95% | -12.8% |
| Q2 2016 | $73,320,000 | +7.8% | 725,947 | +1.3% | 2.23% | +5.5% |
| Q1 2016 | $67,991,000 | +2.4% | 716,763 | +0.2% | 2.12% | -0.7% |
| Q4 2015 | $66,428,000 | +9.4% | 715,205 | +0.4% | 2.13% | +5.1% |
| Q3 2015 | $60,717,000 | +3.8% | 712,559 | +4.3% | 2.03% | +11.4% |
| Q2 2015 | $58,474,000 | +0.4% | 683,186 | -0.4% | 1.82% | +3.9% |
| Q1 2015 | $58,243,000 | -2.4% | 686,006 | -1.4% | 1.75% | -0.1% |
| Q4 2014 | $59,655,000 | +12.4% | 696,013 | -0.4% | 1.75% | +8.1% |
| Q3 2014 | $53,081,000 | -5.5% | 698,609 | -2.0% | 1.62% | -8.6% |
| Q2 2014 | $56,143,000 | +5.7% | 713,109 | +0.6% | 1.77% | +5.3% |
| Q1 2014 | $53,139,000 | +0.7% | 708,525 | +3.7% | 1.68% | +0.8% |
| Q4 2013 | $52,754,000 | +14.0% | 683,342 | +2.4% | 1.67% | +7.2% |
| Q3 2013 | $46,278,000 | +9.5% | 667,596 | -0.1% | 1.56% | +3.0% |
| Q2 2013 | $42,282,000 | – | 667,971 | – | 1.51% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |